Antibiotics

Sources

- Keith Armitage, MD, MACP: https://www.youtube.com/watch?v=3XhBMg499_w
- http://stritch.luc.edu/lumen/meded/therapy/pharm1_blockiv_2011.pdf
- David C. Nguyen, MD
- Clinical Utility Of Oral Cephalosporins Anthony Vecchione, PharmD
- Antibiotics Review for Students, Interns, and Residents MGH Internal Medicine

Key

- * Important to know (for non-ID docs)
- (C) Bactericidal
- S Bacteriostatic
- \oplus Good coverage
- ⊘ − Iffy coverage
- ⊖ Bad coverage


■ Mechanism of action:

- CW Cell wall synthesis inhibitor
- Protein synthesis inhibitor
- NA Nucleic acid synthesis inhibitor
- Met Metabolic inhibitor


■ Mechanism of resistance:


- (Enz) Enzymatic degradation of drug
 - $\{\beta\}$ β -lactamase
- (PBP) Mutation of penicillin binding protein
- (Mut) Mutation of the target
- (Conc) Decrease in intracellular concentration (e.g., mutation in porins, development of efflux pumps)
 - (Seq) Sequestration of drug by proteins

Overview



Drugs





| | Comments | (+++) syphilis, Leptospira GAS, syphilis | UTI, Listeria, Enterococcus | Sinusitis, asp. PNA, bites, cholangitis | Invasive MSSA | Pseudomonas, GI, HCAP | |
|----------------|---------------------|--|-----------------------------|---|---------------------|-----------------------|---|
| | Atypical | (+++) syphilis, $Lept$ | +Lyme | Ø | Ø | Ø | |
| | Anaerobe | ++(month) (| + | ++++ | Ø | +++++ | _ |
| Gram inganive | Normal Pseudomonas | Ø | Ø | Ø | Ø | +++++ | |
| Gran | Normal | + | ‡ | ++++ | Ø | +++++ | |
| | VRE | + 1 | (†) | ‡ | Ø | + | |
| ט | NSE | + 1 | (†) | + | Ø | + | |
| drain positive | MRSA | Ø | Ø | Ø | Ø | Ø | |
| | Strep MSSA MRSA VSE | Ø | Ø | +(| |) + + | |
| | Strep | + + + | ++ | + | + | ++ | |
| | | Penicillin | Amox/amp | Augmentin/Unasyn | Nafcillin/oxacillin | Zosyn | |

Conc • Not susceptible to β -lactamase Generation 1 (C) (CW) – cefazolin* ⊕ Staph (MSSA) \oplus Strep ⊘ Gm− (E. coli, Proteus, Klebsiella) ego Respiratory pathogens (Moraxella, H. influenzae, S. pneumoniae) → Anaerobes ■ Bad CSF penetration Generation 2 (C) (CW) (not important for non-ID docs) – cefuroxime, cefoxitin, cefotetan ⊕ Staph (MSSA) \oplus Strep ⊕ Respiratory pathogens (Moraxella, H. influenzae, S. pneumoniae) Anaerobes ⊘ Gm− \bigcirc Pseudomonas⊖ Enterococcus • Good CSF penetration Generation 3 (C) (CW) – ceftriaxone* ⊕ Staph (MSSA) \oplus Strep \oplus Respiratory pathogens (Moraxella, H. influenzae, S. pneumoniae) Anaerobes ⊕ Gm-⊘ Pseudomonas ⊖ Enterococcus Good CSF penetration

Generation 3.5 (C) CW – ceftazidime

Generation 4 (C) CW – cefepime*

⊕ Gm-

 Θ Gm+

⊕ Gm-

 \oplus Gm+

Pseudomonas

 \oplus Pseudomonas \oplus Enterobacter

- "Nosocomial cephalosporin"
- Neurotoxic (encephalopathy)

Generation 5 (C) (CW) – ceftaroline*

- \oplus MRSA
- ⊕ Enterococcus
- \ominus Pseudomonas
- \ominus Healthcare-associated Gm-

Penicillin Allergy

- If immediate type I hypersensitivity (IgE) \rightarrow <u>not</u> safe to give cephalosporin
- Otherwise (other allergy or no allergy) \rightarrow safe

| | Comments | Skin, cellulitis | Abdominal/pelvic infections | q24h dosing convenient; UTIs; CAP w/ azithro | PO, similar spectrum as ceftriaxone | Febrile neutropenia | Broad GNR coverage | MRSA |
|---------------|-------------------------------------|------------------------|-----------------------------|--|-------------------------------------|---------------------|--------------------|------------------|
| | Atypical | Ø | Ø | CNS or cardiac Lyme | Ø | Ø | Ø | Ø |
| | Anaerobe | Ø | ++ | Ø | Ø | Ø | Ø | Ø |
| Gram negative | VRE Normal Pseudomonas Anaerobe | Ø | Ø | Ø | Ø | ++++ | +++ | Ø |
| Gran | Normal | + | ++ | ++++ | ++ | +++ | +++++ | ++++ |
| | | Ø | Ø | Ø | Ø | Ø | Ø | Ø |
| | $_{ m NSE}$ | Ø | Ø | Ø | Ø | Ø | Ø | Ø |
| Gram positive | MSSA MRSA | Ø | Ø | Ø | Ø | Ø | Ø | + + + + |
| Gra | $_{ m MSSA}$ | ++++ | ++ | ++ | ++ | + | ++ | + + + |
| | Strep | +++ | + | + | + | + | + | ++ |
| | | 1 Cefazolin/cephalexin | 2 Cefotetan | 3 Ceftriaxone | 3 Cefpodoxime | 3 Ceftazidime | 4 Cefipime | 5 Ceftaroline |

Carbapenems C CW Conc Enz PBP

■ Not what they do cover, but what don't they cover?

 $\operatorname{Imipenem} \ \bigodot \ \boxed{\operatorname{CW}}$

- \oslash some Gm- rods
- \ominus MRSA, VRE

Meropenem C CW

• Safer than imipenem (esp., for people with seizure disorder)

Doripenem (C) [CW]

■ Same as meropenem

Ertapenem \bigcirc $\boxed{\text{CW}}$

- \ominus Pseudomonas
- \ominus Enterococcus
- Narrower than other carbapenems
- The once a day carbapenem

| | Comments | Use for ESBL | No Pseudomonas, but convenient dosing |
|---------------|---------------|--------------|---------------------------------------|
| | Atypical | + | + |
| | Anaerobe | ++++ | ++++ |
| Gram negative | Pseudomonas | ++++ | Ø |
| Gran | Normal | +++++ | ++++ |
| | VRE | Ø | Ø |
| е. | VSE | + | Ø |
| Gram positive | MSSA MRSA VSE | Ø | Ø |
| Gra | MSSA | ++++ | ++++ |
| | Strep | ++++ | + + + |
| | | Meropenem | Ertapenem |
| | 8 | 3 | |

Monobactams C CW (B) Conc

■ No immunologic cross-reactivity with β -lactams!

Aztreonam \bigcirc $\boxed{\text{CW}}$

- \oplus Aerobic Gm- rods
- Θ Gm+
- → Anaerobic

| | Comments | Ok in severe penicillin allergy |
|------------|-------------|---------------------------------|
| | Atypical | Ø |
| | Anaerobe | Ø |
| n negative | Pseudomonas | ++ |
| Gran | Normal | +++ |
| | VRE | Ø |
| e | VSE | Ø |
| am positiv | MRSA | Ø |
| G | MSSA | Ø |
| | Strep | Ø |
| | | Aztreonam |

Aminoglycosides C Prot Conc Enz Mut

- Most dangerous of the commonly used antibiotics; safe for a few days, not for >10-14
 - 1. Nephrotoxicity
 - 2a. Ototoxicity
 - 2b. Vestibular* (the least reversible of the toxicities)
 - 3. Neuromuscular
- Toxicities usually temporary (if medication stopped early enough)
- Dosing: once per day
 - ▷ Except in neuropenic fever (controversial)
- ⊕ Gm− aerobes
- → Anaerobes

Gentamicin \bigcirc Prot, tobramycin \bigcirc Prot \rightarrow community-acquired infections

Amikacin \bigcirc Prot \rightarrow nosocomial infections, resistant to aminoglycosidases

| | Comments | Strep or Enterococcus endocarditis (in combination) | VAP (in combination) | Tough UTIs |
|--------------|---------------|---|----------------------|------------|
| | Atypical | Plague, F. tularensis | Ø | Ø |
| | Anaerobe | Ø | Ø | Ø |
| n negative | Pseudomonas | ++ | ++++ | ++ |
| Grar | Normal | +++ | ++++ | ++++++ |
| | VRE | Ø | Ø | Ø |
| ē | $_{ m NSE}$ | Ø | Ø | Ø |
| Fram positiv | MSSA MRSA VSE | ++ | + | + |
| Gr | | ++ | + | + |
| | Strep | ++ | + | + |
| | | Gemtamicin | Tobramycin | Amikacin |

Gm+ agents

Vancomycin © CW Mut

Red man syndrome is an administration error, not an allergy
Linezolid S Prot Mut)

■ Toxicities if used > 2 weeks

Daptomycin (C) (CW) (Conc)

Inactivated by surfactant (cannot be used for lung infections)

Tigecycline (S) Prot (Conc.) (Seq.) (Enz.)

- \ominus Pseudomonas
- \bigcirc Proteus

Doxycycline (S) Prot (Conc) (Seq) (Enz.)

Trimethoprim/sulfamethoxazole (TMP/SMX) (Mut)

- ⊕ MRSA
- ⊕ Gm-
- \ominus Strep pneumoniae
- \ominus GAS
- Allergic toxicity (sulfa \rightarrow SJS/TEN)

Rifampin (C) Prot (Mut)

- Biofilm-associated infection
- High resistance rates with monotherapy; should be paired with another drug
- Revs up CYPs

Clindamycin (S) Prot (Mut)

- \oplus Staph
- Strep
- Anaerobes
- ⊘ MRSA
- Oral infections (high resistance)

Metronidazole (C) NA

- \oplus Obligate anaerobes
- Protozoa
- Can be paired with ceftriaxone (which covers facultative anaerobes)

| | Comments | Measure troughs | MRSA, VRE. Marrow toxicity | MRSA, VRE. Don't use for lung infection | 3rd line, may increase mortality | CAP, atypical infections | Elevates K ⁺ and Cr | GI side effects common | Uncomplicated UTI | Good anaerobe coverage | GNR coverage of last resort | Hepatic encephalopathy |
|---------------|--------------------|-----------------|----------------------------|---|----------------------------------|--------------------------|--------------------------------|------------------------|-------------------|--------------------------|-----------------------------|------------------------|
| | Atypical | Ø | Ø | Ø | Ø | ++++ | P. jirovecii, Nocardia | Babesia | Ø | Some protozoa | Ø | Ø |
| | Anaerobe | C. diff if PO | Ø | Ø | ++++ | Ø | Ø | ++++ | Ø | +++++, including C. diff | Ø | Ø |
| Gram negative | Normal Pseudomonas | Ø | Ø | Ø | Ø | Ø | Ø | Ø | Ø | Ø | ++++ | Ø |
| Gram | Normal | Ø | Ø | Ø | ++++ | Ø | ++ | Ø | ++ | Ø | ++++ | ++ |
| | VRE | Ø | +++ | +++ | +++ | + | Ø | Ø | + | Ø | Ø | Ø |
| e | NSE | +++ | ++++ | ++++ | ++++ | + | Ø | Ø | + | Ø | Ø | Ø |
| Gram positive | MSSA MRSA VSE | ++++ | ++++ | ++++ | ++++ | ++ | ++ | ++ | Ø | Ø | Ø | Ø |
| G | MSSA | + | ++++ | ++++ | ++++ | ++ | +++ | Ø | Ø | Ø | Ø | Ø |
| _ | Strep | +++ | ++ | +++ | +++ | + | + | +++ | + | Ø | Ø | Ø |
| | | Vancomycin | Linezolid | Daptomycin | Tigecycline | Doxycycline | TMP-SMX | Clindamycin | Nitrofurantoin | Metronidazole | Colistin (polymixin E) | Rifaximin |

Quinolones \bigcirc $\boxed{\mathbf{NA}}$

Ciprofloxacin \bigcirc $\boxed{\mathrm{NA}}$

- \oplus Gm- rods
- \oplus Pseudomonas

Levofloxacin \bigcirc $\boxed{\mathrm{NA}}$

- ⊕ Gm− rods
- \oplus Pseudomonas
- $\oplus \ \mathit{Strep pneumoniae}$

Moxifloxacin (C) NA

- \oplus Gm+
- \ominus Gm-

| | | 1S | ansima |
|---------------|-------------------|--------------------|---|
| | Comments | GI, GU infections | Programonia expensive |
| | Atypical | Ø | 7 7 7 |
| | Anaerobe | Ø | Š |
| Gram negative | Pseudomonas | ++ | 4 |
| Grar | SA VSE VRE Normal | + + + | +++++++++++++++++++++++++++++++++++++++ |
| | VRE | Ø | Ø |
| j. | VSE | Ø | 8 |
| ram positive | MRSA | + | + |
| Gra | MSSA | + | + |
| | Strep | Ø | + |
| | | Ciprofloxacin | Levoflowagin |

Macrolides S Prot Conc Mut

Erythromycin \bigcirc Prot] \rightarrow GI motility disorders

Clarithromycin S Prot

 \oplus Strep pneumoniae

- ⊕ Chlamydia (intracellular pathogen)
- High intracellular concentration, low serum concentration

| | | پہ |
|-------------|-------------|----------------|
| | Comments | CAP. chlamvdia |
| | Atypical | +++ |
| | Anaerobe | Ø |
| um negative | Pseudomonas | Ø |
| Gran | Normal | + |
| | VRE | Ø |
| e | A VSE VRE | Ø |
| m positiv | MRSA | Ø |
| Gra | MSSA | + |
| | Strep | ++++ |
| | | Azithromycin |

Anti-fungals

Azoles CW

Ketoconazole CW

Fluconazole CW

 \oplus Candida

Itraconazole CW

Voriconazole CW

- \oplus Aspergillus
- → Molds

Posaconazole CW

Isavuconazole CW

Amphotericin B CW

■ For ID, BMT docs

Echinocandins CW

Micafungin CW

Diseases

UTI

Bugs

- *E. coli*
- lacktriangledown Klebsiella spp.
- Proteus mirabilis

Drugs

- AAP + IDSA guidelines
 - ▷ Cephalexin (1st)
 - ▷ Cefpodoxime (3rd)
- AAP guidelines
 - $\, \rhd \, \, \mathrm{Cefprozil} \, \, (2\mathrm{nd})$
 - ▷ Cefuroxime (2nd)
 - ▷ Cefixime (3rd)
- IDSA guidelines
 - ▷ Cefdinir (3rd)

- AAP guidelines, 2-24 months old (2011)
 - ▷ Cefixime 8 mg/kg daily
 - ▷ Cefpodoxime 10 mg/kg/day divided BID
 - ▷ Cefprozil 30 mg/kg/day divided BID
 - ▷ Cefuroxime 20-30 mg/kg/day divided BID
 - ▷ Cephalexin 50-100 mg/kg/day divided QID
 - \triangleright Not cefdinir

Community-acquired Pneumonia

Bugs

- lacktriangledown Streptococcus pneumoniae
- Haemophilus influenzae
- Mycoplasma pneumoniae
- Chlamydia pneumoniae
- Moraxella catarrhalis
- Staphylococcus aureus

Drugs

| | Penicillin-sensitive S. pneumoniae | Penicillin-intermediate S. pneumoniae | H. influenzae | M. catarrhalis |
|-------------|------------------------------------|---------------------------------------|---------------|----------------|
| Cefdinir | 0 | Θ | \oplus | \oplus |
| Amoxicillin | \oplus | \oplus | \oslash | \ominus |
| Amox-clav | \oplus | \oplus | \oplus | \oplus |
| Ceftriaxone | \oplus | \oplus | \oplus | \oplus |

- Amoxicillin/amoxicillin-clavulanate 90 mg/kg/day divided TID mimics ceftriaxone (S. pneumoniae, H. influenzae, M. catarrhalis)
 - ▷ Oral cephalosporins are inferior
- If PCN-allergic (IDSA)
 - ▶ Trial cephalosporin with good *S. pneumoniae* coverage (e.g., cefpodoxime, cefprozil, cefuroxime)
 - ▷ Cefdinir only for H. influenzae

Osteomyelitis

Bugs

- S. aureus
- Kingella kingae (toddler, preschool)
- S. pyogenes

Drugs

| | MRSA | MSSA | $Kingella\ kingae$ | S. pyogenes | Bone penetration |
|-------------|-----------|-----------|--------------------|-------------|-----------------------|
| Cephalexin | \ominus | \oplus | \ominus | \oplus | Excellent |
| Cefprozol | \ominus | \oplus | \oplus | \oplus | ? |
| Cefuroxime | \ominus | \oplus | \ominus | \oplus | Good |
| Cefdinir | \ominus | \oplus | \oplus | \oplus | ? |
| Cefpodoxime | \ominus | \oplus | \oplus | \oplus | Excellent |
| Cefixime | \ominus | \ominus | \oplus | \oplus | ? |
| Ceftibuten | \ominus | \ominus | \oplus | \oplus | ? |
| TMP-SMX | \oplus | \oplus | \oplus | \oplus | Excellent |
| Clindamycin | \oplus | \oplus | \ominus | \oplus | Excellent |
| Amoxicillin | \ominus | \ominus | \oplus | \oplus | Excellent |
| Amox-clav | Θ | \oplus | \oplus | \oplus | Good |

Thabit, A. International Journal of Infectious Diseases. 4/2019.

Pseudomonas

- **■** PO
 - \triangleright Fluoroquinolones
- IV
 - $\,\triangleright\,$ Piperacillin-tazobactam
 - ▷ Ceftazidime
 - ▷ Cefepime
 - \triangleright Ceftolozane-tazobactam
 - ▶ Aztreonam
 - \triangleright Aminogly cosides
 - ▷ Carbapenems (not ertapenem)
 - ▷ Colistin (polymixin E)